As a third-line drug, erlotinib can inhibit the intracellular tyrosine phosphorylation related to EGFR, which is commonly used for locally advanced or metastatic NSCLC that two or more chemotherapy regimens fail to work on. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.